Drug Formulary Review Archives – April 1, 2004
April 1, 2004
View Issues
-
International societies release historic guidelines for treating sepsis
An international group of critical care professionals has developed the first evidence-based recommendations ever to address the treatment of patients with sepsis. -
Systematic approach taken in evaluating sepsis drug
After the results of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial were published in 2001, many institutions established criteria for use of drotrecogin alfa (activated) that were similar to the inclusion criteria used in the trial. Institutions, however, then had to decide how to evaluate the criteria and the outcomes of patients with sepsis. At one institution, a broad, systematic approach to that evaluation was taken. -
FDA to require bar codes on many drugs and biologics
Pharmacists now can expect thousands of drugs and biological products to have bar codes on their labels by 2006. -
New drug initiatives, task force report announced
The federal government announced several new initiatives recently regarding prescription drugs, as well as the final report from the Counterfeit Drug Task Force. -
News Briefs
Pregnant women concerned about taking asthma medications; Many Americans cut dosages to lessen drug costs, AP poll finds; Talks with docs can result in less expensive drugs for patients; Elderly continue to be prescribed inappropriate medication. -
New FDA Approvals
These drugs recently received final approval from the U.S. Food and Drug Administration (FDA). -
Drug Criteria & Outcomes: Palonosetron (Aloxi) Formulary Evaluation
This second part of the palonosetron formulary evaluation addresses the available clinical trial, adverse effects, and cost analysis data.